Omega-3 Fatty Acids and Neurodegenerative Diseases: New Evidence in Clinical Trials

Int J Mol Sci. 2019 Aug 30;20(17):4256. doi: 10.3390/ijms20174256.


A nutritional approach could be a promising strategy to prevent or slow the progression of neurodegenerative diseases such as Parkinson's and Alzheimer's disease, since there is no effective therapy for these diseases so far. The beneficial effects of omega-3 fatty acids are now well established by a plethora of studies through their involvement in multiple biochemical functions, including synthesis of anti-inflammatory mediators, cell membrane fluidity, intracellular signaling, and gene expression. This systematic review will consider epidemiological studies and clinical trials that assessed the impact of supplementation or dietary intake of omega-3 polyunsaturated fatty acids on neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. Indeed, treatment with omega-3 fatty acids, being safe and well tolerated, represents a valuable and biologically plausible tool in the management of neurodegenerative diseases in their early stages.

Keywords: Alzheimer’s disease; Parkinson’s disease; clinical trials; omega-3 polyunsaturated fatty acids.

Publication types

  • Systematic Review

MeSH terms

  • Clinical Trials as Topic*
  • Fatty Acids, Omega-3 / therapeutic use*
  • Humans
  • Neurodegenerative Diseases / drug therapy*
  • Observational Studies as Topic


  • Fatty Acids, Omega-3